There are however challenges in financing new innovative pharmaceutical projects, and many smaller companies lack access to expertise that can optimize opportunities to benefit from the substantial research grants awarded each year by the EU. Iconovo Accelerator Program is launched to offer customers strategic and operational support in connection with application processes for public funding of projects that are based on the company’s inhaler platforms.

”Many customers in our Novel Pharmaceuticals business segment request professional support in their processes for seeking EU funding to their development projects, and we are proud to have established a qualified process to accelerate the development of new inhalation products. By strengthening our customers’ financing capacity, we enhance the conditions for implementing collaborative projects in a time-efficient and professional manner. This in turn has potential to increase our earnings capacity,” says Johan Wäborg, CEO of Iconovo.

About Argentum
Argentum is a consultancy firm that specializes in optimizing the opportunities for its clients to obtain financial support for research projects from the EU. The company is part of the FreeMind Group, which has helped secure research and development funding of around EUR 2 billion for international clients since its inception in 1999.